United Medical
This article was originally published in The Gray Sheet
Executive Summary
Plans to go private via a $9.50 per share cash offer for 48% of the 2.6 mil. shares of United Medical stock outstanding. The remaining 52% of United's stock is held by Chairman John Aglialoro and President Joan Carter, who will retain ownership of the company. There "is no financing contingency for the transaction," which is expected to close 30 days after receipt of approval by the company's public shareholders and the consent of existing lenders. Among reasons cited by the company for going private is that United Medical stock has typically traded below book value, which currently is $10.27 per share. The stock closed at $6.375 on Dec. 31 -- the last trading day before the company's Jan. 4 announcement -- and at $9.25 on Jan. 4....
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.